Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Roche says Venetoclax combination improves PFS in phase III CLL trial By PBR Staff Writer
Roche has reported that its cancer drug Venclexta/Venclyxto (venetoclax), developed jointly with AbbVie, has succeeded in a phase 3 study in chronic lymphocytic leukaemia (CLL) patients by meeting its primary endpoint.
Contract Research & Services > Clinical Trials > News
Bydureon EXSCEL trial shows favorable cardiovascular safety profile in patients with type-2 diabetes AstraZeneca has announced full results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type-2 diabetes (T2D) at a wide range of CV risk.
Contract Research & Services > Clinical Trials > News Vanda's tradipitant improves itch and disease severity in patients with atopic dermatitis Vanda Pharmaceuticals announced results from an eight-week randomized phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Amicus Therapeutics’ skin disorder drug SD-101 fails in phase 3 trial
By PBR Staff Writer
Amicus Therapeutics’ skin disorder drug SD-101 has failed to meet the primary endpoints and secondary endpoints in a phase 3 Essence clinical study.
Contract Research & Services > Clinical Trials > News
Onxeo’s liver cancer drug Livatag fails in phase 3 trial
By PBR Staff Writer
French biotechnology company Onxeo has announced that its liver cancer drug Livatag (doxorubicine Transdrug) failed to meet the primary endpoint in a phase 3 trial in adult patients with unresectable hepatocellular carcinoma (HCC).
Contract Research & Services > Clinical Trials > News
AstraZeneca’s Imfinzi lung cancer drug shows significant effect in PACIFIC trial
AstraZeneca and MedImmune have presented the full PFS data from a planned interim analysis of the phase III PACIFIC trial.
Contract Research & Services > Clinical Trials > News
IRX Therapeutics reports positive IRX-2 phase 2a head and neck squamous cell carcinoma clinical results
IRX Therapeutics has presented results from a Phase 2a clinical trial of IRX-2, the company’s lead drug candidate, in head and neck squamous cell carcinoma (SCCHN) at the European Society for Medical Oncology (ESMO) Annual Congress 2017.
Contract Research & Services > Clinical Trials > News
Teva’s migraine drug fremanezumab succeeds in phase 3 studies
By PBR Staff Writer
Teva Pharmaceutical has reported that its migraine drug fremanezumab had succeeded in its phase 3 HALO studies by meeting all its 25 primary and secondary endpoints.
Contract Research & Services > Clinical Trials > News
Kura Oncology reports positive phase 2 study for Tipifarnib in HRAS mutant head and neck cancer
Kura Oncology has announced positive topline results from a phase 2 trial for its lead product candidate, tipifarnib, in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC).
Contract Research & Services > Clinical Trials > News
AstraZeneca’s COPD drug Duaklir meets primary endpoints in phase III Amplify trial
By PBR Staff Writer
AstraZeneca’s Duaklir (aclidinium bromide/formoterol 400µg/12µg twice-daily) has met its primary endpoints in the Phase III Amplify trial of patients with chronic obstructive pulmonary disease (COPD).
Contract Research & Services > Clinical Trials > News
Roche’s lung cancer drug Alecensa shows significant effect in global phase III study
By PBR Staff Writer
Roche’s lung cancer drug Alecensa (alectinib) has showed significant effect in the phase III ALUR study.
Contract Research & Services > Clinical Trials > News
Midatech submits MTD201 CTA filing for first in human study in carcinoid cancer and acromegaly
Midatech Pharma has announced the submission of a clinical trial application (CTA) for a first in human study of its MTD201 programme in carcinoid cancer and acromegaly.
Contract Research & Services > Clinical Trials > News
Novartis multiple sclerosis drug Gilenya shows siginificant effect in phase III trial
By PBR Staff Writer
Novartis’ multiple sclerosis (MS) drug Gilenya (fingolimod) has demonstrated significant effect in the phase III Paradigms study.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests